company background image
2552 logo

Hua Medicine (Shanghai) SEHK:2552 Stock Report

Last Price

HK$1.33

Market Cap

HK$1.2b

7D

-11.9%

1Y

-30.4%

Updated

22 Jul, 2024

Data

Company Financials

Hua Medicine (Shanghai) Ltd.

SEHK:2552 Stock Report

Market Cap: HK$1.2b

2552 Stock Overview

Operates as a drug development company that focuses on therapies for the treatment of diabetes in China.

2552 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 2552 from our risk checks.

Hua Medicine (Shanghai) Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hua Medicine (Shanghai)
Historical stock prices
Current Share PriceHK$1.33
52 Week HighHK$2.78
52 Week LowHK$1.16
Beta1.6
11 Month Change-18.40%
3 Month Change-16.35%
1 Year Change-30.37%
33 Year Change-68.63%
5 Year Change-80.97%
Change since IPO-83.94%

Recent News & Updates

Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Nov 17
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Recent updates

Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Nov 17
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

Aug 28
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

Jan 06
We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Aug 02
We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Apr 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Sep 23
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Jun 24
We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Mar 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Feb 21
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Jan 25
Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Dec 21
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Shareholder Returns

2552HK PharmaceuticalsHK Market
7D-11.9%-0.6%-4.7%
1Y-30.4%-4.8%-1.4%

Return vs Industry: 2552 underperformed the Hong Kong Pharmaceuticals industry which returned -4.8% over the past year.

Return vs Market: 2552 underperformed the Hong Kong Market which returned -1.4% over the past year.

Price Volatility

Is 2552's price volatile compared to industry and market?
2552 volatility
2552 Average Weekly Movement7.3%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement6.8%
10% most volatile stocks in HK Market14.4%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 2552's share price has been volatile over the past 3 months.

Volatility Over Time: 2552's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011177Li Chenwww.huamedicine.com

Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease.

Hua Medicine (Shanghai) Ltd. Fundamentals Summary

How do Hua Medicine (Shanghai)'s earnings and revenue compare to its market cap?
2552 fundamental statistics
Market capHK$1.19b
Earnings (TTM)-HK$226.78m
Revenue (TTM)HK$82.25m

15.9x

P/S Ratio

-5.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2552 income statement (TTM)
RevenueCN¥76.61m
Cost of RevenueCN¥39.24m
Gross ProfitCN¥37.37m
Other ExpensesCN¥248.61m
Earnings-CN¥211.23m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin48.78%
Net Profit Margin-275.73%
Debt/Equity Ratio122.6%

How did 2552 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.